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2		
Abstract	
Background:	Pharmacy-driven	 transitions	of	care	 (TOC)	services	 for	patients	with	psychiatric	disorders	
have	not	been	systematically	evaluated.		
	
Objective:	 The	 primary	 objective	 was	 to	 assess	 the	 frequency	 of	 TOC	 services	 that	 were	 delivered.	
Secondary	objectives	were	 to	evaluate	 the	 incidences	of	psychiatric-associated	 re-hospitalizations	and	
outpatient	clinic	follow-up	thirty	days	post-discharge.		
		
Methods:	 This	 retrospective,	 double-cohort	 study	 compares	 adult	 patients	who	 received	 at	 least	 one	
pharmacy-driven	 TOC	 intervention	 prior	 to	 being	 discharged	 from	 a	 psychiatric	 unit	 between	 June	 1,	
2017	and	June	30,	2018	to	a	historical	control	group	that	was	discharged	between	June	1,	2016	and	May	
31,	 2017.	 Interventions	 included	 discharge	 counseling	 on	 select	 high-risk	 medications,	 medication	
barrier	 assessments,	 delivery	 of	 TOC	 notes	 to	 outpatient	 providers,	 post-discharge	 telephone	
communication,	and	bedside	delivery	of	medications.		
		
Results:	A	total	of	157	health	records	were	reviewed.	The	most	common	interventions	were	discharge	
education	 (44.2%),	 bedside	 delivery	 of	 medications	 (44.2%),	 and	 medication	 barriers	 assessments	
(43.3%).	Adherence	(38.5%)	and	cost	(27.9%)	were	the	most	common	medication	barriers.	Thirty-day	re-
hospitalizations	 occurred	 in	 32.4%	 and	 15.4%	 of	 patients	 in	 the	 control	 and	 intervention	 groups,	
respectively	(P	<	 	0.001).	A	total	of	15.1%	and	20.1%	of	patients	presented	for	outpatient	follow-up	 in	
the	control	and	intervention	groups,	respectively	(P	<		0.001).		
		
Conclusion:	 The	 findings	 demonstrate	 a	 significant	 association	 between	 receiving	 pharmacy-driven	
transitional	 interventions	 and	 enhanced	 clinical	 outcomes	 for	 this	 patient	 population.	 Future	
prospective	studies	are	warranted	to	further	elucidate	these	observations.		
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Introduction	
The	 United	 States	 (U.S.)	 healthcare	 system	 is	 considerably	 burdened	 by	 hospital	 readmissions.	
Medicare	 data	 suggests	 that	 readmissions	 within	 30	 days	 of	 hospital	 discharge	 represent	 20%	 of	 all	
hospital	admissions,	costing	approximately	$17	billion	annually.1	This	national	burden	has	influenced	the	
establishment	of	 the	Hospital	Readmissions	and	Reduction	Program	 (HRRP)	under	 the	provisions	of	 the	
Affordable	Care	Act.	The	HRRP	is	a	Medicare	value-based	payment	program	that	reduces	reimbursements	
to	 hospitals	 with	 excessive	 readmissions	 that	 are	 associated	 with	 acute	 myocardial	 infarction,	 heart	
failure,	 pneumonia,	 chronic	 obstructive	 pulmonary	 disease	 (COPD),	 and	 elective	 total	 hip	 and/or	 knee	
arthroplasty.2	Consequently,	many	healthcare	systems	have	begun	to	develop	strategies	to	enhance	the	
coordination	of	care	between	inpatient	and	outpatient	clinical	services	through	transitions	of	care	(TOC)	
initiatives.		
As	 medication	 experts,	 pharmacists	 are	 uniquely	 qualified	 to	 contribute	 to	 hospital	 TOC	 by	
optimizing	 medication	 therapy,	 improving	 the	 accuracy	 of	 medication	 lists,	 providing	 patient-centered	
medication	recommendations,	promoting	medication	adherence,	and	providing	medication	education	to	
providers	 and	 patients.3	 Through	 their	 involvement,	 pharmacists	 contribute	 to	 health	 system	 goals	 of	
reducing	preventable	adverse	drug	events,	enhancing	patient	outcomes,	and	decreasing	overutilization	of	
healthcare	 resources.4-6	 It	 is	 well	 established	within	 the	 literature	 that	 pharmacist	 involvement	 in	 TOC	
enhances	 medication	 compliance	 and	 reduces	 hospital	 readmissions	 among	 patients	 with	 various	
conditions	such	as	 infectious	diseases,	heart	failure,	and	COPD.7-9	For	 instance,	a	recent	study	evaluated	
the	 impact	 of	 pharmacist-mediated	 transitional	Medication	 Therapy	Management	 (MTM)	 interventions	
(e.g.,	 comprehensive	medication	 reconciliation,	 disease	 state	 education,	 safety/efficacy	monitoring)	 for	
adult	patients	who	were	discharged	with	diagnoses	of	congestive	heart	failure,	COPD,	or	pneumonia.	The	
findings	demonstrate	a	significant	reduction	in	30-day	readmissions	(20%	and	6.9%	for	standard	care	and	
intervention	 groups,	 respectively)	 for	 patients	 that	 received	 these	 MTM	 services.10	 Unfortunately,	
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pharmacy	 TOC	 interventions	 targeting	 patients	 with	 psychiatric	 and	 behavioral	 health	 issues	 have	 not	
been	systematically	evaluated.		
Previous	studies	have	examined	how	medication-related	 factors	 influence	hospital	 readmissions	
among	 high	 utilizers	 of	 hospital	 resources,	 such	 as	 patients	 with	 psychiatric	 disorders.	 These	 findings	
demonstrated	that	30-day	readmission	rates	at	the	study	site	were	common,	non-adherence	to	discharge	
medications	 occurred	 in	 approximately	 half	 of	 patients,	 and	 a	 more	 complex	 psychotropic	 medication	
regimen	and	a	higher	psychotropic	medication	count	at	discharge	were	associated	with	a	shorter	time	to	
readmission.11,12	These	findings	have	influenced	pharmacy	clinicians	at	the	study	site	to	develop	and	pilot	
new	TOC	interventions	for	adult	patients	with	psychiatric	disorders.	
Existing	literature	also	suggests	additional	medication-related	considerations	that	may	aid	in	this	
effort	to	enhance	patient	outcomes	through	pharmacy-driven	TOC	interventions,	particularly	by	targeting	
the	 complexity	 of	 medication	 regimens.13-15	 The	 medication	 regimen	 complexity	 index	 (MRCI)	 is	 a	
validated,	 electronic	 65-item	 instrument	 developed	 by	 the	 University	 of	 Colorado	 Skaggs	 School	 of	
Pharmacy	 and	 Pharmaceutical	 Sciences	 that	 can	 be	 used	 in	 clinical	 settings	 to	 assess	 the	 medication	
regimen	complexity	of	both	prescribed	and	over-the-counter	(OTC)	medications.15	The		numerical	values	
that	 comprise	 the	 MRCI	 provide	 healthcare	 professionals	 with	 objective	 clinical	 information	 to	 make	
reasonable	predictive	assessments	of	a	patient’s	ability	to	self-manage	their	medication	regimen	as	well	
as	their	likely	outcomes.		
The	 primary	 objective	 of	 this	 study	 is	 to	 describe	 the	 types	 and	 frequency	 of	 pharmacy	 TOC	
interventions	 provided	 for	 adult	 patients	 who	 were	 hospitalized	 for	 psychiatric	 services.	 Secondary	
objectives	are	 to	evaluate	 the	differences	between	patient	outcomes,	such	as	psychiatric-associated	re-
hospitalizations	(i.e.,	admission	to	a	psychiatric	unit	or	any	psychiatric-associated	emergency	department	
(ED)	utilization)	and	outpatient	clinic	 follow-up	within	 thirty	days	 following	hospital	discharge.	Although	
not	 a	major	 focus	 of	 this	 study,	 a	 tertiary	 objective	was	 to	 evaluate	 the	 differences	 in	MRCI	 between	
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intervention	and	historical	control	groups	for	psychotropic,	non-psychotropic,	OTC,	and	total	medication	
regimens.		
	
Methods	
This	 study	was	designed	as	a	 retrospective,	double	cohort	chart	 review	and	was	exempt	by	 the	
Institutional	Review	Board	(IRB)	at	the	study	site.	Patients	who	were	discharged	from	one	of	the	two	adult	
(i.e.,	age	≥	18	years)	inpatient	psychiatric	units	at	the	study	site	between	June	1,	2017	and	June	30,	2018	
and	 received	 one	 or	 more	 of	 the	 enhanced	 pharmacy-driven	 TOC	 services	 during	 their	 hospitalization	
qualified	for	inclusion	in	the	intervention	group	and	were	reviewed	retrospectively.	Enhanced	pharmacy-
driven	 interventions	 included	 medication	 barrier	 assessments,	 provision	 of	 discharge	 TOC	 notes	 to	
outpatient	 providers,	 bedside	 delivery	 of	 discharge	 medications,	 discharge	 education	 on	 high-risk	
medications,	 and	 post-discharge	 telephone	 communication	 with	 patients	 who	 were	 deemed	 by	 the	
pharmacy	 clinician	 to	 be	 at	 substantially	 high-risk	 for	 re-hospitalization,	 defined	 as	 those	 with	 access	
issues	 to	 medications	 (e.g.,	 uninsured),	 history	 of	 frequent	 hospitalizations,	 or	 prescribed	 medications	
requiring	 frequent	 laboratory	 monitoring	 (i.e.,	 lithium	 and	 clozapine).	 The	 factors	 assessed	 within	 the	
medication	 barriers	 assessments	were	 adherence,	 cost,	 transportation,	 history	 of	 adverse	 drug	 events,	
and	medication	complexity.	This	information	was	either	obtained	from	preexisting	health	records	or	from	
patient	interviews	following	patient	admission	to	one	of	the	psychiatric	units.		
Patients	 who	 had	 psychiatric	 diagnoses	 but	 were	 hospitalized	 on	 medical	 units	 other	 than	
psychiatry	and	neurosciences	were	excluded	from	this	study.	Patients	comprising	the	intervention	group	
were	compared	to	a	historical	control	group	consisting	of	patients	who	were	discharged	from	one	of	the	
two	same	adult	psychiatric	units	as	the	intervention	group	from	June	1,	2016	to	May	31,	2017,	which	was	
prior	to	the	implementation	of	enhanced	pharmacy	TOC	interventions.	The	MRCI	for	total,	psychotropic,	
non-psychotropic,	 and	 OTC	medication	 regimens	 was	 determined	 to	 further	 characterize	 patients.	 For	
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study	outcomes,	“re-hospitalization”	was	defined	as	readmission	to	one	of	the	psychiatric	units	and	any	
psychiatric-associated	utilization	of	the	ED.			
Two	 distinct	 patient	 lists	 were	 generated	 that	 included	 uniquely	 identifiable	 medical	 record	
numbers	of	patients	who	were	discharged	during	the	time	periods	of	interests	for	both	the	intervention	
and	 control	 groups.	 Patients	 comprising	 the	 historical	 control	 group	 were	 randomly	 selected	 from	 a	
cohort	of	patients	who	were	discharged	from	the	same	psychiatric	units	during	a	time	in	which	enhanced	
pharmacy	TOC	services	within	psychiatry	were	not	offered.	The	following	demographic	data	was	collected	
for	 all	 patients:	 patient	 age,	 sex,	 ethnicity,	 primary	 psychiatric	 diagnosis,	 insurance	 status,	 length	 of	
current	 hospitalization,	 number	 of	 previous	 psychiatric-associated	 hospitalizations	 within	 the	 previous	
year,	and	number	and	type	of	medications	on	discharge.		
New	patient	care	note	templates	were	developed	within	the	institution’s	electronic	health	record	
database	 in	order	to	standardize	the	documentation	of	TOC	services.	The	specific	TOC	services	received	
by	each	patient	were	identified	to	quantify	type	and	frequency.	Patient	electronic	records	were	screened	
for	the	incidence	of	outpatient	clinic	follow-up,	as	well	as	re-hospitalizations	within	30	days	of	discharge.	
Information	pertaining	to	MRCI	was	captured	from	discharge	notes	 listed	within	patient	health	records.	
The	MRCI	was	calculated	by	analyzing	pharmacy	data	such	as	dosage	form,	frequency	of	dosing,	number	
of	 distinct	 medications,	 multiple	 doses	 of	 the	 same	 medication,	 dietary	 or	 time	 requirements,	 and	
administrative	directions	for	each	medication	on	discharge.	MRCI	scores	were	calculated	for	psychotropic	
medications,	non-psychotropic	medications,	OTC	medications,	and	an	aggregated	total	MRCI	score.			
	
Statistical	Analysis		
Descriptive	statistics	were	utilized	to	assess	the	primary	objective	and	the	independent	t-test	was	
used	to	compare	MRCI	scores,	rates	of	re-hospitalization,	and	rates	of	outpatient	follow-up	between	the	
control	 and	 intervention	 groups.	 A	 chi-square	 analysis	 utilizing	 Quantpsy	 Computer	 Software	 was	
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performed	 to	 detect	 baseline	 differences	 between	 groups.	 A	 minimum	 of	 50	 patients	 for	 both	
intervention	and	control	groups	was	necessary	 to	achieve	adequate	power	of	80%	utilizing	a	one-tail	 t-
test	with	 an	 effect	 size	 of	 0.5.	 The	 one-tail	 t-test	was	 determined	by	 utilizing	Microsoft	 Excel.	 Findings	
with	a	p-value	of	less	than	0.05	were	considered	statistically	significant.			
	
Results	
Baseline	Characteristics		
A	 total	 of	 157	 patient	 health	 records	were	 selected	 for	 retrospective	 chart	 review.	 There	were	
several	 significant	 baseline	 differences	 between	 groups	 (Table	 1).	 Most	 notably,	 significantly	 more	
patients	 presented	 with	 primary	 psychiatric	 diagnoses	 of	 schizophrenia	 or	 bipolar	 disorder	 within	 the	
intervention	group	compared	to	the	control	group.	There	were	significantly	more	patients	presenting	with	
depression	in	the	control	group	compared	to	the	intervention	group.	Additionally,	there	were	significantly	
more	 patients	 who	 had	 at	 least	 one	 hospital	 admission	 in	 the	 previous	 year,	 were	 uninsured,	 had	 a	
documented	history	of	non-adherence,	and	experienced	a	longer	duration	of	index	hospitalization	in	the	
intervention	group	as	compared	to	the	control	group.		
Evaluation	of	TOC	Services		
	 A	total	of	203	pharmacy	TOC	services	were	provided	to	patients	in	the	intervention	group	during	
the	13-month	period	 that	 these	 services	were	piloted.	As	demonstrated	 in	Figure	1,	 the	most	 common	
TOC	interventions	were	discharge	education,	bedside	delivery	of	discharge	medications,	and	medication	
barriers	 assessments.	 Of	 the	 medication	 barriers	 assessments,	 adherence	 and	 cost	 were	 the	 most	
commonly	 reported.	 The	mean	number	of	 interventions	 received	by	each	patient	was	2.1.	 The	 level	 of	
pharmacy	 personnel	 who	 delivered	 these	 services	 was	 also	 recorded.	 Twelve	 student	 pharmacists	 on	
inpatient	 rotations,	 3	 student	 pharmacists	 on	 ambulatory	 care	 rotations,	 9	 pharmacy	 residents	 on	
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inpatient	rotations,	and	3	clinical	pharmacy	specialists	were	involved	in	the	delivery	of	TOC	services	over	
the	course	of	a	13-month	period.		
Evaluation	of	Secondary	and	Tertiary	Objectives		
As	 demonstrated	 in	 Figure	 2,	 the	 incidence	 of	 readmissions	 and	 ED	 utilization	 30	 days	 after	
hospital	discharge	was	significantly	lower	in	the	intervention	group	than	in	the	control	group	(P	<	0.001).	
Additionally,	the	incidence	of	outpatient	follow-up	in	the	intervention	group	was	significantly	higher	than	
follow-up	in	the	control	group	(P	<	0.001).	The	average	time	to	outpatient	follow-up	was	30	and	21.8	days	
for	control	and	intervention	groups,	respectively	(P	=	0.7).		
Upon	discharge,	 the	psychotropic	MRCI	was	7.7	and	6.0	 in	 the	 intervention	and	control	groups,	
respectively	 (P	 =	 0.01).	 The	 average	 numbers	 of	 psychotropic	medications	 upon	 discharge	 per	 patient	
were	1.8	and	3.9	 for	 the	 control	 and	 intervention	groups,	 respectively.	 There	were	no	other	 significant	
differences	 in	 MRCI	 between	 intervention	 and	 control	 groups	 for	 non-psychotropic,	 OTC,	 and	 total	
medication	 regimens	 at	 admission	 or	 upon	 discharge	 (Table	 2).	 The	 following	 values	 represent	 the	
percentage	 of	 psychotropic	medications	 at	 discharge	 in	 the	 control	 group	 for	 antidepressants,	 lithium,	
mood	 stabilizers	 other	 than	 lithium,	 clozapine,	 and	 antipsychotics	 other	 than	 clozapine,	 respectively:	
41.8%,	4.3%,	1.7%,	0.9%,	and	25.7%.	Conversely,	 the	respective	number	of	psychotropic	medications	at	
discharge	 in	 the	 intervention	 group	 for	 antidepressants,	 lithium,	 mood	 stabilizers	 other	 than	 lithium,	
clozapine,	 and	 antipsychotics	 other	 than	 clozapine	 were:	 25.9%,	 10.9%,	 1.9%,	 2.6%,	 and	 58.9%,	
respectively.		
	
Discussion		
The	 findings	 demonstrate	 a	 statistically	 significant	 association	 between	 pharmacy	 TOC	 services	
and	improvement	in	early	outcomes	within	30	days	of	hospital	discharge,	reflecting	a	number	needed	to	
treat	of	5.3	 to	prevent	30-day	 re-hospitalizations	and	19.6	 to	 improve	 the	 show-rate	of	 first	outpatient	
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clinic	 follow-up.	This	data	also	highlights	 the	 implementation	of	a	wide	array	of	pharmacy	TOC	services	
within	 psychiatry	 through	 a	 dedicated	 service	 that	 provided	meaningful	 continuity	 of	 care.	 Though	not	
directly	 measured,	 such	 services	 may	 increase	 the	 value	 of	 patient	 care	 within	 psychiatry	 and	 reduce	
healthcare	costs.	These	findings	also	indicate	the	potential	benefit	of	including	psychiatry	as	an	additional	
disease	 state	 for	 targeted	 TOC	 services	 alongside	 COPD,	 asthma,	 heart	 failure,	 infectious	 diseases,	 and	
diabetes.		
As	 previously	 mentioned,	 pharmacy	 TOC	 interventions	 in	 psychiatric	 patient	 populations	 are	
considerably	 underrepresented	 in	 the	 literature.	 To	our	 knowledge,	 this	 is	 not	 only	 the	 first	 study	 that	
specifically	examines	the	impact	of	pharmacy	TOC	services	in	this	patient	population,	but	it	is	also	the	first	
study	 to	 suggest	 a	 clinical	 benefit	 through	 implementation	 of	 such	 services.	 Considering	 that	 studies	
assessing	 pharmacy	 TOC	 interventions	 within	 psychiatry	 are	 limited,	 the	 TOC	 services	 that	 were	
implemented	and	discussed	in	this	study	were	largely	adapted	from	a	systematic	review	that	reports	on	
physician	 and	 nurse-led	 TOC	 interventions	 for	 patients	 with	 psychiatric	 disorders.16	 Interventions	
discussed	 in	 this	 systematic	 review	were	 either	 implemented	 during	 the	 inpatient	 admission,	 the	 early	
post-discharge	period,	or	spanned	the	transition	from	inpatient	to	outpatient	care.	Services	included	pre-
discharge	 psycho-education	 interventions,	 needs	 assessments,	 medication	 education,	 and	 medication	
reconciliation.	Early	post-discharge	and	bridging	services	included	efforts	to	ensure	timely	follow-up	such	
as	 scheduling	 follow-up	 appointments	 prior	 to	 discharge,	 telephone	 follow-up,	 home	 visits,	 and	 post	
discharge	needs	assessments.16	 Likewise,	pharmacy	personnel	 in	our	study	were	able	 to	 implement	our	
services	with	 a	 goal	 of	 targeting	 the	 transitions	 from	 early	 hospital	 admission,	 discharge	 planning,	 and	
outpatient	coordination	and	follow-up.	The	enhanced	pharmacy	TOC	services	described	in	our	study	were	
largely	developed	based	on	these	findings	and	the	perceived	feasibility	in	implementing	each	service.		
Much	 of	 the	 pharmacy	 TOC	 services	 discussed	 in	 our	 study	 focused	 on	 assessing	 medication-
related	 barriers	 and	 resolving	 those	 barriers	 through	 improving	 access	 to	 medications,	 providing	
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medication	education,	coordinating	with	outpatient	providers,	and	re-emphasizing	care	plans	with	high-
risk	patients	following	their	discharge	through	telephone	communication.	Of	note,	implementation	of	the	
TOC	 services	discussed	 in	 this	 study	 required	notable	 adaptations	 considering	 that	 the	 aforementioned	
nursing	 and/or	 physician-led	 services	 did	 not	 have	 a	 primary	 focus	 on	 the	 continuity	 of	 care	 through	
medication	management,	which	was	a	core	focus	of	the	enhanced	pharmacy	TOC	services.		As	a	result	of	
these	 modifications,	 unique	 challenges	 to	 implementing	 pharmacy-driven	 TOC	 interventions	 were	
identified.	 	For	 instance,	 the	nurse-to-patient	 ratio	 is	 typically	 relatively	higher	 in	most	 institutions	 than	
the	 pharmacist-to-patient	 ratio	 considering	 the	 various	 needs	 that	 patients	 require	 at	 the	 bedside	 by	
nurses.	 The	gap	 in	 this	 ratio	between	nursing	and	pharmacy	 coverage	 is	 likely	even	higher	within	most	
psychiatry	departments.	This	trend	initially	presented	a	challenge	to	the	implementation	of	the	pharmacy-
TOC	 interventions	 that	 have	been	discussed	but	was	 improved	with	 the	 inclusion	of	 pharmacy	 student	
and	 resident	 learners	as	pharmacy	personnel	 to	deliver	 these	services.	 In	doing	so,	 the	pharmacy	 team	
was	able	 to	better	accommodate	 the	needs	of	 the	patients	 involved	 in	 this	 study	and	 to	work	 towards	
enhancing	their	continuity	of	care.		
The	 expanded	 role	 of	 delivering	 these	 services	 by	 pharmacy	 student	 and	 resident	 learners	
involved	additional	training	so	that	the	learners	would	be	able	to	identify	patients	who	might	benefit	from	
pharmacy	TOC	services.	Specifically	for	discharge	TOC	services	(i.e.,	discharge	medication	education	and	
post-discharge	telephone	follow-up),	patients	in	the	intervention	group	might	have	been	largely	identified	
for	 such	 services	 based	 on	 medication	 regimen	 (i.e.,	 lithium	 and	 clozapine)	 and	 uninsured	 status	 as	
indicators	 of	 higher	 risk	 or	 greater	 need	 for	 optimal	medication	management	 and	 effective	 bridging	 to	
outpatient	care.	Of	all	of	the	TOC	interventions	that	were	implemented,	the	majority	of	patients	received	
some	 form	 of	 discharge	 education.	 Considering	 that	 adherence	 was	 the	 most	 prevalent	 medication	
barrier	 identified,	 pharmacy	 personnel	 likely	 targeted	 TOC	 strategies,	 such	 as	 discharge	 medication	
education	 and	 post-discharge	 telephone	 follow	 up,	 to	 aid	 in	 improving	 medication	 adherence	 in	 the	
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outpatient	setting.	The	idea	that	the	pharmacy	team	targeted	measures	that	would	address	adherence	is	
further	supported	by	what	has	been	reported	about	medication	adherence	in	patients	with	schizophrenia	
and	bipolar	disorder.	 In	 a	 systematic	 review	of	 38	 studies,	 it	 has	been	proposed	 that	 the	mean	 rate	of	
non-adherence	to	psychoactive	medications	in	bipolar	and	schizophrenia	clinical	trials	is	58%,	with	ethnic	
minority	 and	barriers	 to	 care	 reported	 as	 risk	 factors	 to	non-adherence.17	 Based	on	 those	 findings,	 the	
higher	number	of	patients	with	bipolar	disorder	and	schizophrenia	 in	 the	 intervention	group	relative	 to	
the	control	group	in	our	study	may	indicate	that	these	high-risk	disease	states	may	benefit	most	from	TOC	
services	although	additional	analyses	are	required	to	assess	 impact	on	adherence.	 	Although	adherence	
was	 not	 formally	 assessed	 in	 this	 study,	 studies	 evaluating	 the	 associations	 between	 the	 delivery	 of	
pharmacy	 TOC	 services	 and	 improved	 adherence	 are	 warranted	 based	 on	 the	 practical	 rate	 of	 non-
adherence	among	patients	with	psychiatric	disorders,	namely	bipolar	and	schizophrenia.		
Unlike	the	positive	outcomes	seen	on	30-day	readmissions	and	outpatient	follow-up,	there	were	
no	 clinically	 positive	 or	meaningful	 differences	 for	MRCI	 between	 groups,	 suggesting	 perhaps	 that	 the	
impact	 of	 pharmacy	 TOC	 services	 have	 less	 influence	on	medication	 complexity	 (i.e.,	MRCI)	 but	 have	 a	
stronger	 influence	on	 interventions	 focused	on	continuity	of	care	and	outpatient	 follow-up.	This	 finding	
may	 be	 of	 particular	 relevance	 to	 pharmacy	 practice	 considering	 that	 many	 pharmacists	 do	 not	 have	
prescribing	authority	and	must	 rely	on	a	prescriber’s	acceptance	of	 their	 recommendations	 to	alter	 the	
complexity	 of	medication	 regimens.	Nonetheless,	 the	 pharmacy	 TOC	 services	 that	were	 provided	were	
able	to	enhance	patient	outcomes	despite	the	challenge	of	pharmacists	not	having	prescribing	authority.	
For	 instance,	 majority	 of	 patients	 in	 this	 study	 received	 discharge	 medication	 education	 or	 bedside	
delivery	of	medications.	It	is	possible	that	these	TOC	services	were	delivered	in	response	to	the	identified	
medication	 barriers	 surrounding	 medication	 complexity,	 which	 accounted	 for	 13.5%	 of	 the	 total	
medication	 barriers	 that	 were	 identified.	 Although	 these	 services	 did	 not	 have	 a	 direct	 impact	 on	
medication	complexity,	the	findings	suggest	that	patients	benefited	from	improved	access	to	their	high-
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risk	medications	 through	bedside	delivery,	and	with	ensured	discharged	medication	education	on	those	
high-risk	medications	upon	delivery.	The	significant	reductions	in	re-hospitalizations	and	improvements	in	
outpatient	 follow-up	 suggest	 that	 these	 interventions	 targeted	 equipping	 patients	 with	 the	 ability	 to	
better	 understand	 and	 manage	 their	 complex	 regimens	 with	 a	 goal	 of	 improving	 continuity	 of	 care.	
Although	these	services	did	not	have	a	direct	impact	on	medication	complexity,	the	findings	suggest	that	
patients	 benefited	 from	 improved	 access	 to	 their	 high-risk	 medications	 through	 bedside	 delivery	 of	
medications	 as	 well	 as	 discharge	 medication	 education	 on	 those	 high-risk	 medications.	 Finally,	 the	
intervention	 group	 had	 more	 complex	 issues	 compared	 to	 the	 control	 group,	 such	 as	 higher	 rates	 of	
previous	 psychiatric	 readmissions	 and	 diagnoses	 of	 schizophrenia	 and	 bipolar	 disorder,	 illnesses	 that	
often	require	complex	regimens	in	the	acute	phase.	These	circumstances	likely	made	reductions	in	MRCI	
more	difficult	to	achieve	considering	that	consolidation	of	medication	regimens	for	psychiatric	inpatients	
may	 be	 challenged	 during	 the	 acute	 periods	 when	 polypharmacy	 is	 likely	 to	 occur	 for	 symptom	
management.	 Nonetheless,	 the	 findings	 suggest	 that	 pharmacists	 are	 still	 able	 to	 improve	 patient	
outcomes	 by	 preparing	 patients	 with	 relatively	 high	 medication	 regimen	 complexity	 for	 successful	
discharge	and	bridging	to	outpatient	care.		
The	 delivery	 of	 TOC	 services	 for	 patients	 with	 psychiatric	 disorders	 was	 a	 collaborative	 effort	
between	 a	 psychiatric	 clinical	 pharmacy	 team	 and	 pharmacy	 learners	 to	 develop	 and	 implement	 an	
innovative	model	showing	positive	associations	between	delivery	of	pharmacy	TOC	services	and	enhanced	
continuity	 of	 care.	 Thoughtful	 and	 collaborative	 development	 of	 a	 standardized	 process	 involving	 all	
psychiatric	 pharmacy	 personnel,	 including	 student	 and	 resident	 learners,	 resulted	 in	 either	 the	
implementation	 of	 entirely	 new	 services	 or	 enhanced	 pre-existing	 services	 in	 the	 development	 of	 a	
process	to	improve	continuity	of	care	for	this	patient	population.	Notably,	approximately	50%	of	patients	
received	post-discharge	telephone	communication	and	medication	barrier	assessments,	which	were	the	
newest	 interventions	 of	 the	 TOC	 services.	 The	 primary	 finding	 of	 evaluating	 the	 type	 and	 frequency	 of	
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enhanced	TOC	services	not	only	demonstrates	that	the	implementation	of	pharmacy-driven	TOC	services	
can	 expand	 the	 types	 of	 services	 offered	 to	 patients,	 but	 the	 findings	 also	 demonstrate	 additional	 and	
unique	 opportunities	 for	 pharmacy	 learners	 to	 become	 engaged	 in	 patient	 care	 throughout	 the	 entire	
transitional	process.		
There	 are	 additional	 limitations	 to	 our	 study	 not	 already	 addressed.	 The	 ability	 to	 consistently	
provide	 services	was	 limited	 by	 the	 availability	 of	 pharmacy	 personnel	 to	 implement	 the	 TOC	 services.	
This	was	 initially	a	challenge	due	 to	 the	onboarding	and	comprehensive	TOC	training	 that	was	 required	
prior	to	involving	pharmacy	residents	and	student	pharmacists	in	the	delivery	of	these	services.	After	the	
learners	 were	 adequately	 trained,	 inconsistent	 scheduling	 of	 learners	 on	 psychiatric	 rotations	 further	
challenged	 implementation.	 Considering	 that	 these	 services	 were	 implemented	 at	 a	 large	 academic	
teaching	hospital	with	substantial	pharmacy	resources,	 it	 is	 likely	that	smaller	community	hospitals	may	
find	 it	 more	 difficult	 to	 overcome	 these	 challenges	 if	 attempting	 to	 implement	 similar	 TOC	 services	
without	 similar	 resources.	 There	 were	 also	 differences	 in	 baseline	 demographics	 between	 the	
intervention	 and	 historical	 control	 groups.	 Interestingly	 though,	 one	 might	 hypothesize	 that	 the	
differences	would	categorize	the	intervention	group	as	more	complex	or	severe,	and	less	likely	to	achieve	
a	significant	outcome,	however	that	was	not	the	case	in	some	of	the	study	findings.	Also,	post-discharge	
or	bridging	interventions	accounted	for	only	a	small	percent	of	total	TOC	interventions.	Further	expansion	
of	these	TOC	services	to	outpatient	care	would	allow	for	more	opportunities	to	impact	patient	outcomes	
after	 hospital	 discharge	 in	 this	 patient	 population	 which	 is	 often	 lost	 to	 follow-up.	 Nonetheless,	 the	
findings	 suggest	 that	 pharmacy	 TOC	 services	 may	 enhance	 continuity	 of	 care	 and	 reduce	 re-
hospitalizations	despite	 the	complexity	of	medication	 regimens.	This	may	be	clinically	meaningful	when	
managing	patients	who	are	difficult	to	treat	or	unable	to	tolerate	medication	consolidation.	Considering	
the	 retrospective	 design	 of	 this	 study,	 additional	 exploration	 of	 these	 findings	 in	 prospective	 trials	 is	
warranted	to	further	elucidate	these	findings.	Specifically,	future	prospective	studies	may	be	enhanced	by	
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incorporating	an	evaluation	of	the	rate	of	physician	acceptance	to	pharmacy	recommendations,	the	time	
commitment	to	perform	TOC	services,	as	well	as	a	cost	savings	analysis	to	further	demonstrate	the	value	
of	pharmacy	TOC	services	to	healthcare	institutions.	
	
Conclusion	
The	 implementation	 of	 pharmacy-driven	 TOC	 services	 expanded	 upon	 the	 common	 types	 of	
services	 that	psychiatric	patients	 receive	as	 seen	 in	 the	existing	 literature.	 Integration	of	 these	 services	
provided	targeted	interventions	for	this	patient	population,	which	they	had	not	previously	received	as	a	
standardized	process,	and	have	allowed	for	improved	continuity	of	care	despite	factors	that	may	limit	the	
ability	 of	 pharmacists	 to	 alter	 the	 complexity	 of	 medication	 regimens.	 This	 study	 expands	 the	 current	
body	 of	 literature	 and	 provides	 clinical	 guidance	 for	 pharmacy	 personnel	 to	 implement	 pharmacy	 TOC	
interventions	that	have	been	associated	with	improved	clinical	outcomes.		
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Appendix	
	
Table	1:	Patient	Baseline	Characteristics,	n=	157	
Characteristic	 Control	(n	=	53)	 Intervention	(n=	104)	 p-value	
Average	age,	years	(range)	 37.8	(18	-	63)	 40.3	(18	-	72)	 0.31	
Race,	n	(%)	
Caucasian	
African	American	
Hispanic	
Asian	
Other	
	
40	(75.5)	
10	(18.9)	
0	(0.0)	
0	(0.0)	
3	(5.7)	
	
61	(58.7)	
31	(29.9)	
3	(2.8)	
2	(1.9)	
12	(11.5)	
	
<	0.01	
0.02	
<	0.01	
<	0.01	
<	0.01	
Gender,	n	(%)	
Male	
Female	
	
25	(47.2)	
28	(52.8)	
	
51	(49.0)	
54	(51.9)	
	
0.8	
0.7	
Primary	psychiatric	disorder,	n	
(%)	
Depression	
PTSD		
Schizophrenia	
Anxiety	
Bipolar	disorder	
Suicidal	Ideation	
Substance	Abuse	
Hallucinations	
Personality	Disorder	
Other	
	
	
25	(47.2)	
3	(5.6)	
7	(13.2)	
0	(0.0)	
6	(11.3)	
4	(7.5)	
5	(9.4)	
0	(0.0)	
1	(1.9)	
2	(3.8)	
	
	
24	(23.1)	
3	(2.9)	
24	(23.1)	
3	(2.9)	
28	(26.9)	
6	(5.8)	
1	(0.9)	
4	(3.8)	
1	(0.9)	
20	(27.9)	
	
	
<	0.01	
<	0.01	
<	0.01	
<	0.01	
<	0.01	
0.1	
<	0.01	
<	0.01	
<	0.01	
<	0.01	
Admission	within	previous	year,	
n	(%)	
15	(28.3)	 40	(38.5)	 0.01	
History	of	Medication	Non-
adherence	(%)	
26	(49.1)	 58	(55.8)	 <	0.01	
Average	Length	of	
Hospitalization,	days	(range)	
	
10.1	(2-41)	
	
16.1	(1-87)	
	
<	0.01	
Insurance	status		
Uninsured	
Private	
Medicaid	
Medicare	Part	D	
	
10	(18.9)	
19	(35.8)	
17	(32.1)	
7	(13.2)	
	
40	(38.5)	
19	(18.3)	
31	(30.0)	
14	(13.5)	
	
<	0.01	
0.03	
0.15	
<	0.01	
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Figure	1:	Distribution	of	TOC	Services,	n	(%)	
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Figure	2:	Assessment	of	Secondary	Endpoints,	n	(%)	
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Table	2:	Evaluation	of	Medication	Regimen	Complexity,	n	(%)	
	 Psychotropic,	avg	
(median)	
Non-psychotropic,	avg	
(median)	
OTC,	avg	
(median)	
Total,	avg	(median)	
Admission	
			Control	
			Intervention	
			P	value		
	
5.86	(5.5)	
6.1	(5.5)	
0.8	
	
4.99	(3.25)	
6.4	(4.0)	
0.3	
	
3.93	(3.0)	
3.1	(2.0)	
0.2	
	
15.1	(14.0)	
15.5	(13.0)	
0.7	
Discharge	
			Control	
			Intervention	
			P	value	
	
6.0	(4.5)	
7.7	(7.5)	
0.01	
	
9.8	(5.0)	
7.2	(5.0)	
0.09	
	
3.4	(0.0)	
3.8	(2.0)	
0.7	
	
19.2	(16.5)	
18.7	(18.0)	
0.9	
	
